GlassScriptPhysician profile
Kimberly M Persley
NPI 1255375770
$5,487.21
in general payments reported to CMS, 2019-2025
22 companies · $945 in 2025
The $945 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $60.02 · 2021: $509 · 2022: $1,045 · 2023: $1,260 · 2024: $1,314 · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,511 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,511.22 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,149.35 | 2019-2025 | |
| Pfizer INC. | $806.62 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $706.59 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $405.09 | 2022-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $245.46 | 2019-2024 | Dificid |
| Janssen Scientific Affairs, LLC | $220.54 | 2022-2024 | Tremfya, Stelara |
| Janssen Biotech, INC. | $162.76 | 2019-2024 | Stelara, Simponi Aria, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.17 | 2020-2025 | Relistor, Trulance, Xifaxan |
| Ardelyx, INC. | $127.97 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $121.70 | 2023 | |
| Madrigal Pharmaceuticals | $59.59 | 2025 | Rezdiffra |
| Lilly USA, LLC | $53.01 | 2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $49.15 | 2022 | |
| Ferring Pharmaceuticals INC. | $44.61 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $44.39 | 2019-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $43.19 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.93 | 2023-2024 | Cyltezo |
| Genzyme Corporation | $28.63 | 2024 | |
| Nestle Healthcare Nutrition INC. | $17.37 | 2023 | |
| Alfasigma USA, INC. | $14.37 | 2020 | |
| Vivus LLC | $13.72 | 2025 | Qsymia |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Persley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.